A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial.
from Top Health News -- ScienceDaily https://ift.tt/2ZOk6Us
Health, Fitness,Dite plan, health tips,athletic club,crunch fitness,fitness studio,lose weight,fitness world,mens health,aerobic,personal trainer,lifetime fitness,nutrition,workout,fitness first,weight loss,how to lose weight,exercise,24 hour fitness,
Labels
Technology
New Post
[recent][newsticker]
MKRdezign
Powered by Blogger.
Post a Comment